https://www.mynewsdesk.com/se/anocca-ab Mynewsdesk RSS - Press releases, News, and Blog Posts. https://www.mynewsdesk.com/se/anocca-ab https://www.mynewsdesk.com/assets/graphics/logos/logo-small-9892f98564f91864075bd14001f8470f2f9bf254729c37044b4b1ac9b0db6b40.png 128 23 en 15 Mon, 18 Aug 2025 09:05:02 +0200 https://www.mynewsdesk.com/se/anocca-ab/pressreleases/anocca-tar-in-440-miljoner-kronor-foer-klinisk-proevning-mot-bukspottkoertelcancer-3398850?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/anocca-ab/pressreleases/anocca-tar-in-440-miljoner-kronor-foer-klinisk-proevning-mot-bukspottkoertelcancer-3398850?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Anocca AB Wed, 16 Apr 2025 15:47:45 +0200 I sitt senaste reportage i Onkologi i Sverige lyfter Ulrika Nyberg fram vårt arbete på Anocca – ett svenskt biotechbolag som nu är på väg in i klinik med nästa generations TCR-T-cellterapi. I artikeln får läsaren inblick i hur svensk teknologi, ingenjörskonst och systemtänkande kan utmana globala strukturer inom cancervård. Finns här en historia som rör mer än bara vetenskap. https://www.mynewsdesk.com/se/anocca-ab/news/svensk-bioteknik-paa-vaeg-att-foeraendra-spelplanen-onkologi-i-sverige-496424?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/anocca-ab/news/svensk-bioteknik-paa-vaeg-att-foeraendra-spelplanen-onkologi-i-sverige-496424?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Anocca AB Mon, 17 Mar 2025 09:01:00 +0100 https://www.mynewsdesk.com/se/anocca-ab/pressreleases/anocca-har-faatt-myndighetsgodkaennande-att-starta-klinisk-studie-paa-patienter-med-avancerad-bukspottkoertelcancer-3374896?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/anocca-ab/pressreleases/anocca-har-faatt-myndighetsgodkaennande-att-starta-klinisk-studie-paa-patienter-med-avancerad-bukspottkoertelcancer-3374896?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Anocca AB Fri, 28 Feb 2025 10:43:25 +0100 https://www.mynewsdesk.com/se/anocca-ab/news/the-tcr-t-cell-therapies-of-tomorrow-494560?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/anocca-ab/news/the-tcr-t-cell-therapies-of-tomorrow-494560?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Anocca AB Mon, 24 Feb 2025 11:30:00 +0100 https://www.mynewsdesk.com/se/anocca-ab/news/from-refugee-to-qa-slash-qc-a-journey-of-opportunity-and-growth-494407?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/anocca-ab/news/from-refugee-to-qa-slash-qc-a-journey-of-opportunity-and-growth-494407?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Anocca AB Tue, 26 Nov 2024 09:00:00 +0100 https://www.mynewsdesk.com/se/anocca-ab/pressreleases/anocca-announces-submission-of-clinical-trial-application-for-multi-asset-trial-vidar-1-in-advanced-pancreatic-cancer-3371980?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/anocca-ab/pressreleases/anocca-announces-submission-of-clinical-trial-application-for-multi-asset-trial-vidar-1-in-advanced-pancreatic-cancer-3371980?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Anocca AB Thu, 07 Nov 2024 09:00:00 +0100 https://www.mynewsdesk.com/se/anocca-ab/news/home-grown-production-talent-494415?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/anocca-ab/news/home-grown-production-talent-494415?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Anocca AB Fri, 20 Sep 2024 20:00:00 +0200 https://www.mynewsdesk.com/se/anocca-ab/news/swedens-anocca-is-a-tcr-t-company-with-a-unique-approach-that-is-going-after-unique-targets-its-first-cta-will-be-filed-soon-494528?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/anocca-ab/news/swedens-anocca-is-a-tcr-t-company-with-a-unique-approach-that-is-going-after-unique-targets-its-first-cta-will-be-filed-soon-494528?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Anocca AB Mon, 09 Sep 2024 09:00:00 +0200 https://www.mynewsdesk.com/se/anocca-ab/pressreleases/anocca-presents-data-at-esmo-congress-on-preclinical-development-of-its-tcr-t-cell-therapies-for-cancer-3371975?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/anocca-ab/pressreleases/anocca-presents-data-at-esmo-congress-on-preclinical-development-of-its-tcr-t-cell-therapies-for-cancer-3371975?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Anocca AB Fri, 31 May 2024 09:00:00 +0200 https://www.mynewsdesk.com/se/anocca-ab/pressreleases/anocca-utser-christiane-hanke-harloff-till-styrelsen-3371967?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/anocca-ab/pressreleases/anocca-utser-christiane-hanke-harloff-till-styrelsen-3371967?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Anocca AB Thu, 30 May 2024 09:00:00 +0200 Co-developing immune-evasive allogeneic TCR-iPS-T-cell therapies for the treatment of solid tumors https://www.mynewsdesk.com/se/anocca-ab/pressreleases/anocca-ab-and-shinobi-therapeutics-announce-strategic-partnership-to-develop-allogeneic-tcr-t-cell-therapies-in-oncology-3371968?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/anocca-ab/pressreleases/anocca-ab-and-shinobi-therapeutics-announce-strategic-partnership-to-develop-allogeneic-tcr-t-cell-therapies-in-oncology-3371968?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Anocca AB Thu, 14 Mar 2024 09:00:00 +0100 Stödjer utvecklingen av Anoccas breda pipeline av T-cellsterapier (TCR-T) https://www.mynewsdesk.com/se/anocca-ab/pressreleases/anocca-ab-licensierar-genredigeringsteknologi-fraan-emendobio-inc-3371970?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/anocca-ab/pressreleases/anocca-ab-licensierar-genredigeringsteknologi-fraan-emendobio-inc-3371970?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Anocca AB Tue, 13 Feb 2024 09:00:00 +0100 https://www.mynewsdesk.com/se/anocca-ab/pressreleases/anocca-utser-martin-welschof-till-styrelsen-3371955?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/anocca-ab/pressreleases/anocca-utser-martin-welschof-till-styrelsen-3371955?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Anocca AB Tue, 30 Jan 2024 09:00:00 +0100 Nordens största anläggning för tillverkning av cellterapier för klinisk prövning https://www.mynewsdesk.com/se/anocca-ab/pressreleases/anocca-saekrar-gmp-tillverkningslicens-foer-att-avancera-nya-kras-tcr-t-cellterapier-in-i-klinisk-utveckling-3371953?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/anocca-ab/pressreleases/anocca-saekrar-gmp-tillverkningslicens-foer-att-avancera-nya-kras-tcr-t-cellterapier-in-i-klinisk-utveckling-3371953?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Anocca AB Fri, 02 Jun 2023 09:00:00 +0200 https://www.mynewsdesk.com/se/anocca-ab/news/anocca-raises-36-dollars-dot-6m-for-large-scale-development-of-cancer-cell-therapies-494519?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/anocca-ab/news/anocca-raises-36-dollars-dot-6m-for-large-scale-development-of-cancer-cell-therapies-494519?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Anocca AB Tue, 23 May 2023 09:30:00 +0200 https://www.mynewsdesk.com/se/anocca-ab/pressreleases/anocca-genomfoer-en-nyemission-om-400-miljoner-kronor-foer-storskalig-utveckling-av-cellterapier-mot-cancer-3371936?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/anocca-ab/pressreleases/anocca-genomfoer-en-nyemission-om-400-miljoner-kronor-foer-storskalig-utveckling-av-cellterapier-mot-cancer-3371936?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Anocca AB Thu, 22 Dec 2022 09:30:00 +0100 https://www.mynewsdesk.com/se/anocca-ab/pressreleases/anocca-saekrar-25-miljoner-euro-fraan-europeiska-investeringsbanken-eib-foer-att-stoedja-klinisk-utveckling-av-naesta-generations-t-cellsterapier-foer-cancer-3371933?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/anocca-ab/pressreleases/anocca-saekrar-25-miljoner-euro-fraan-europeiska-investeringsbanken-eib-foer-att-stoedja-klinisk-utveckling-av-naesta-generations-t-cellsterapier-foer-cancer-3371933?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Anocca AB Wed, 21 Dec 2022 14:42:00 +0100 https://www.mynewsdesk.com/se/anocca-ab/news/straabergs-laekemedelsbolag-fortsaetter-ta-in-maangmiljonbelopp-494419?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/anocca-ab/news/straabergs-laekemedelsbolag-fortsaetter-ta-in-maangmiljonbelopp-494419?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Anocca AB Fri, 23 Jul 2021 09:00:00 +0200 https://www.mynewsdesk.com/se/anocca-ab/news/finanskaendisar-investerar-i-anocca-tar-in-400-miljoner-494517?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/anocca-ab/news/finanskaendisar-investerar-i-anocca-tar-in-400-miljoner-494517?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Anocca AB Sun, 06 Jun 2021 07:00:00 +0200 https://www.mynewsdesk.com/se/anocca-ab/news/arbetsloesa-tilda-21-fick-en-chans-och-tog-den-upptaecktes-av-bioteknikfoeretaget-trodde-jag-aldrig-i-min-vildaste-fantasi-494418?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/anocca-ab/news/arbetsloesa-tilda-21-fick-en-chans-och-tog-den-upptaecktes-av-bioteknikfoeretaget-trodde-jag-aldrig-i-min-vildaste-fantasi-494418?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Anocca AB